A uniform and versatile surface-guided radiotherapy procedure and workflow for high-quality breast deep-inspiration breath-hold treatment in a multi-center institution.

PURPOSE: We share our experiences on uniformly implementing an effective and efficient SGRT procedure with a new clinical workflow for treating breast patients in deep-inspiration breath-hold (DIBH) among 9 clinical centers using 26 optical surface imaging (OSI) systems. METHODS: Our procedures have five major components: (1) acquiring both free-breathing (FB) and DIBH computed tomography (CT) at simulation to quantify the rise of the anterior surface, (2) defining uniformly a large region of interest (ROI) to accommodate large variations in patient anatomy and treatment techniques, (3) performing two-step setup in FB by first aligning the arm and chin to minimize breast deformation and reproduce local lymphnode positions and then aligning the ROI, (4) aligning the vertical shift precisely from FB to DIBH, and (5) capturing a new on-site reference image at DIBH to separate residual setup errors from the DIBH motion monitoring uncertainties. Moreover, a new clinical workflow was developed for patient data preparation using 4 OSI offline workstations without interruption of SGRT treatment at 22 OSI online workstations. This procedure/workflow is suitable for all photon planning techniques, including 2-field, 3-field, 4-field, partial breast irradiation (PBI), and volumetric-modulated arc therapy (VMAT) with or without bolus. RESULTS: Since 2019, we have developed and applied the uniform breast SGRT DIBH procedure with optimized clinical workflow and ensured treatment accuracy among the nine clinics within our institution. About 150 breast DIBH patients are treated daily and two major upgrades are achieved smoothly throughout our institution, owing to the uniform and versatile procedure, adequate staff training, and efficient workflow with effective clinical supports and backup strategies. CONCLUSION: The uniform and versatile breast SGRT DIBH procedure and workflow have been developed to ensure smooth and optimal clinical operations, simplify clinical staff training and clinical troubleshooting, and allow high-quality SGRT delivery in a busy multi-center institution.

Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.

PURPOSE: In the KATHERINE study (NCT01772472), patients with HER2-positive early breast cancer (EBC) and residual invasive disease after neoadjuvant chemotherapy plus HER2-targeted therapy who were treated with adjuvant trastuzumab emtansine (T-DM1) had a 50% reduction in the risk of an invasive disease-free survival (IDFS) event compared to patients treated with adjuvant trastuzumab. In metastatic disease, T-DM1 has resulted in higher rates of thrombocytopenia in Asian versus non-Asian patients. Here, we report safety and efficacy in Chinese patients from KATHERINE. METHODS: Patients with HER2-positive EBC and residual invasive disease after taxane- and trastuzumab-containing neoadjuvant chemotherapy followed by surgery were randomized 1:1 to 14 cycles of adjuvant T-DM1 or trastuzumab. The primary endpoint was time to an IDFS event. RESULTS: Among Chinese patients (T-DM1 n = 51, trastuzumab n = 50), T-DM1 treatment resulted in a 43% reduction in risk of an IDFS event compared to trastuzumab (HR = 0.57; 95% CI 0.25-1.31), with similar results for secondary endpoints. As in the global population, Chinese patients receiving T-DM1 versus trastuzumab had more grade ≥ 3 adverse events (AEs; 39.2% versus 4.1%) and AEs leading to treatment discontinuation (27.5% versus 0%). The most common grade ≥ 3 AE with T-DM1 was thrombocytopenia (21.6%), a frequency higher than the frequency in the global population (5.7%). Grade ≥ 3 hemorrhage was reported in 1 patient (T-DM1 arm). CONCLUSIONS: In the KATHERINE study, T-DM1 demonstrated increased efficacy compared to trastuzumab in Chinese patients. Consistent with previous data in Asian patients, T-DM1 was associated with more grade ≥ 3 AEs, and AEs leading to discontinuation, which was driven by an increase in thrombocytopenia.

Evaluation scale to assess the accuracy of cuff-less blood pressure measuring devices.

OBJECTIVE: The call for early detection of hypertension and cardiac events creates a heavy demand for devices that can be used for blood pressure (BP) monitoring at home and in ambulatory settings. An emerging type of BP monitors without an occluding cuff has drawn great attentions for this application because it is comfortable and capable of providing continuous readings. For the development the cuff-less devices, it is crucial for the clinicians and engineers to joint efforts in establishing an evaluation standard. METHODS: This study attempts to contribute to its initiation in two ways. First, a new distribution model for measurement differences between the test device and the reference was proposed. We verified the model using evaluation results from 40 devices, of which 80% of the American Association for the Advancement of Medical Instrumentation and British Hypertension Society reporting results were in agreement, as compared with 50%, if the original normal model was used. We further tested a cuff-less device on 85 patients for 999 datasets and found that the differences between the proposed distribution and that of the device were nonsignificant for systolic BP measurements (Kolmogorov-Smirnov = 0.036, P = 0.15). Second, some evaluation scales were studied for their capability to assess the accuracy of cuff-less devices. For mean absolute difference, a map was developed to relate it with the criteria of American Association for the Advancement of Medical Instrumentation, British Hypertension Society, and European Society of Hypertension protocols, on the basis of the proposed distribution model; for mean absolute percentage difference, it is prominent in evaluating devices that have measurement errors often increasing with BP, which is an issue has not been fully explored in existing standards. CONCLUSION: This study focused on the statistical aspect of establishing standard to assess the accuracy of cuff-less BP measuring devices. The results of our study on the validation reports of various cuff-based devices and an experimental study on a cuff-less device showed that the t4 distribution is better than the normal distribution in portraying the underlying error distribution of both kinds of devices. Moreover, based on both the theoretical and experimental studies, mean absolute difference or mean absolute percentage difference is recommended as continuous scale to assess the accuracy of cuff-less devices for their own distinctive advantages.

A protocol design for evaluation of wearable cuff-less blood pressure measuring devices.

This paper proposes one of the unique requirements in the validation protocol of the IEEE P1708 standard in assessing wearable cuff-less blood pressure (BP) measuring devices. Based on principles that are different from that of the conventional cuff-based devices, the cuff-less BP measurement approaches often require an individual calibration procedure. In this study, we used data from an experiment carried out on 28 subjects with a total of 139 sets of BP measurements as an example to show that breakdown of the performance evaluation of cuff-less devices according to the change of BP from the point of calibration is crucial for understanding and interpreting the overall accuracy of the device.